The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1200
January 17, 2005
View Complete Issue         Table of Contents 2019 
Apomorphine (Apokyn) for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Apomorphine (Apokyn) for Parkinson's Disease
January 17, 2005 (Issue: 1200)
Apomorphine (Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with advanced Parkinson's disease. It has been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Apomorphine (Apokyn) for Parkinson's Disease
Article code: 1200b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.